Literature DB >> 26055811

Osteogenesis imperfecta: pathophysiology and treatment.

Heike Hoyer-Kuhn1, Christian Netzer, Oliver Semler.   

Abstract

Osteogenesis imperfecta is a rare hereditary disease mostly caused by mutations impairing collagen synthesis and modification. Recently recessive forms have been described influencing differentiation and activity of osteoblasts and osteoclasts. Most prominent signs are fractures due to low traumata and deformities of long bones and vertebrae. Additional patients can be affected by dwarfism, scoliosis Dentinogenesis imperfecta, deafness and a blueish discoloration of the sclera. During childhood state of the art medical treatment are i.v. bisphosphonates to increase bone mass and to reduce fracture rate. Surgical interventions are needed to treat fractures, to correct deformities and should always be accompanied by physiotherapeutic and rehabilitative interventions.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26055811     DOI: 10.1007/s10354-015-0361-x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  29 in total

1.  Lack of circulating pigment epithelium-derived factor is a marker of osteogenesis imperfecta type VI.

Authors:  Frank Rauch; Abdallah Husseini; Peter Roughley; Francis H Glorieux; Pierre Moffatt
Journal:  J Clin Endocrinol Metab       Date:  2012-06-05       Impact factor: 5.958

2.  Fassier-Duval femoral rodding in children with osteogenesis imperfecta receiving bisphosphonates: functional outcomes at one year.

Authors:  Joanne Ruck; Noémi Dahan-Oliel; Kathleen Montpetit; Frank Rauch; François Fassier
Journal:  J Child Orthop       Date:  2011-05-08       Impact factor: 1.548

3.  Heterogeneity in osteogenesis imperfecta: clinical and morphological findings.

Authors:  B F Pontz; H Stöss; J Spranger
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

4.  Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw.

Authors:  Evelina Maines; Elena Monti; Francesco Doro; Grazia Morandi; Paolo Cavarzere; Franco Antoniazzi
Journal:  J Bone Miner Metab       Date:  2011-11-08       Impact factor: 2.626

5.  Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.

Authors:  Davide Gatti; Franco Antoniazzi; Rosangela Prizzi; Vania Braga; Maurizio Rossini; Luciano Tatò; Ombretta Viapiana; Silvano Adami
Journal:  J Bone Miner Res       Date:  2004-12-20       Impact factor: 6.741

Review 6.  Osteogenesis imperfecta.

Authors:  Frank Rauch; Francis H Glorieux
Journal:  Lancet       Date:  2004-04-24       Impact factor: 79.321

Review 7.  New genes in bone development: what's new in osteogenesis imperfecta.

Authors:  Joan C Marini; Angela R Blissett
Journal:  J Clin Endocrinol Metab       Date:  2013-06-14       Impact factor: 5.958

8.  Two years' experience with denosumab for children with osteogenesis imperfecta type VI.

Authors:  Heike Hoyer-Kuhn; Christian Netzer; Friederike Koerber; Eckhard Schoenau; Oliver Semler
Journal:  Orphanet J Rare Dis       Date:  2014-09-26       Impact factor: 4.123

9.  Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.

Authors:  Eric S Orwoll; Jay Shapiro; Sandra Veith; Ying Wang; Jodi Lapidus; Chaim Vanek; Jan L Reeder; Tony M Keaveny; David C Lee; Mary A Mullins; Sandesh C S Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

10.  A mutation in the 5'-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus.

Authors:  Oliver Semler; Lutz Garbes; Katharina Keupp; Daniel Swan; Katharina Zimmermann; Jutta Becker; Sandra Iden; Brunhilde Wirth; Peer Eysel; Friederike Koerber; Eckhard Schoenau; Stefan K Bohlander; Bernd Wollnik; Christian Netzer
Journal:  Am J Hum Genet       Date:  2012-08-02       Impact factor: 11.043

View more
  8 in total

Review 1.  Osteogenesis imperfecta in children and adolescents-new developments in diagnosis and treatment.

Authors:  P Trejo; F Rauch
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

2.  Effect of Bisphosphonates on Function and Mobility Among Children With Osteogenesis Imperfecta: A Systematic Review.

Authors:  Christopher S Constantino; Joseph J Krzak; Alissa V Fial; Karen M Kruger; Jacob R Rammer; Katarina Radmanovic; Peter A Smith; Gerald F Harris
Journal:  JBMR Plus       Date:  2019-10-18

3.  Up-regulated IL-17 and Tnf signaling in bone marrow cells of young male osteogenesis imperfecta mice.

Authors:  Chenyi Shao; Yi Liu; Jiaci Li; Ziyun Liu; Yuxia Zhao; Yaqing Jing; Zhe Lv; Ting Fu; Zihan Wang; Guang Li
Journal:  PeerJ       Date:  2022-08-23       Impact factor: 3.061

4.  Morphological Study of Dental Structure in Dentinogenesis Imperfecta Type I with Scanning Electron Microscopy.

Authors:  Andrea Martín-Vacas; Manuel Joaquín de Nova; Belén Sagastizabal; Álvaro Enrique García-Barbero; Vicente Vera-González
Journal:  Healthcare (Basel)       Date:  2022-08-02

Review 5.  Tissue Engineering Through 3D Bioprinting to Recreate and Study Bone Disease.

Authors:  Adriene Pavek; Christopher Nartker; Maamoon Saleh; Matthew Kirkham; Sana Khajeh Pour; Ali Aghazadeh-Habashi; Jared J Barrott
Journal:  Biomedicines       Date:  2021-05-14

6.  High bone mass phenotype in a cohort of patients with Osteogenesis Imperfecta caused due to BMP1 and C-propeptide cleavage variants in COL1A1.

Authors:  E H Campanini; D Baker; P Arundel; N J Bishop; A C Offiah; S Keigwin; S Cadden; E Dall'Ara; N Nicolaou; S Giles; J A Fernandes; M Balasubramanian
Journal:  Bone Rep       Date:  2021-07-01

7.  Effects of a telescopic intramedullary rod for treating patients with osteogenesis imperfecta of the femur.

Authors:  D L Rosemberg; E O Goiano; M Akkari; C Santili
Journal:  J Child Orthop       Date:  2018-02-01       Impact factor: 1.548

8.  Novel mutation of FKBP10 in a pediatric patient with osteogenesis imperfecta type XI identified by clinical exome sequencing.

Authors:  Harvy Mauricio Velasco; Jessica L Morales
Journal:  Appl Clin Genet       Date:  2017-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.